Last reviewed · How we verify
A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF
A Phase II Trial With Radiotherapy Plus Cetuximab to Evaluate Specific Survival Free of Laryngectomy in Patients With Resectable and Locally Advanced Larynx Cancer, After Treatment With TPF Chemotherapy.
Details
| Lead sponsor | Grupo Español de Tratamiento de Tumores de Cabeza y Cuello |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 94 |
| Start date | 2008-10 |
| Completion | 2015-05-12 |
Conditions
- Head and Neck Cancer
Interventions
- TPF, radiotherapy and cetuximab
- H&N surgery
Primary outcomes
- Specific survival free of total laryngectomy — Three years after the end of treatment with radiotherapy and cetuximab
Time from the start of TPF treatment to death caused by the disease or by the treatment of the disease, or even to surgery involving total laryngectomy. Deaths caused by other reasons were considered "censored" data on the date of death.
Countries
Spain